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ABSTRACT
Background: Milk-alkali syndrome is a life-threatening condition defined by the triad of hypercalcaemia, metabolic alkalosis and acute renal 
failure, and is associated with consumption of calcium and absorbable alkali.
Methods: We report the case of a patient admitted to a step-down unit of a large hospital in Italy.
Results: The patient was a 59-year-old woman with hypoparathyroidism and mild chronic kidney insufficiency, treated for a preceding 
episode of hypocalcaemia with high doses of calcitriol and calcium carbonate, who was also taking hydrochlorothiazide and unreported 
herbal anthranoid laxatives. The patient was admitted to hospital with severe hypercalcaemia, severe metabolic alkalosis and acute renal 
insufficiency. The patient was successfully treated with urgent dialysis, loop diuretics and calcitonin administration. 
Conclusions: This case underlines the need for caution when treating patients with impaired calcium metabolism regulation, and suggests 
that herbal anthranoid laxatives might act as triggers for milk-alkali syndrome.
LEARNING POINTS
• Patients with hypoparathyroidism are more prone to develop milk-alkali syndrome.
• Patients need careful follow-up and review of their need for calcium supplements.
• Non-prescription and complementary medicines can aggravate hypercalcaemia.
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CASE DESCRIPTION 
Hypercalcaemia, metabolic alkalosis and acute renal failure, associated with oral intake of high doses of calcium and absorbable alkali, is 
known as milk-alkali syndrome. This is a life-threatening condition if not properly diagnosed and treated, whose incidence is rising due to 
the more frequent therapeutic use of calcium carbonate[1]. Here we present the case of a patient with hypoparathyroidism and mild chronic 
renal insufficiency, who was treated with high doses of calcitriol and calcium carbonate while also taking a hydrochlorothiazide and herbal 
anthranoid laxatives. 
METHODS AND RESULTS
An obese, 59-year-old woman with mild chronic renal insufficiency, hypothyroidism and hypoparathyroidism secondary to a radical 
thyroidectomy performed 8 years previously for papillary thyroid cancer, presented after falling at home and complained of weakness, 
dizziness, unsteadiness, numbness and confusion lasting a week. The patient also had hypertension, and was under oral anticoagulant 
therapy after aortic valve replacement with a mechanical valve.
The patient had been discharged a month before after being hospitalized in the orthopaedic ward for a phlegmon of the second toe of 
the left foot, which was complicated with sepsis and subsequently required amputation. During her hospital stay, due to the sepsis and 
treatment with two loop diuretics (furosemide and torasemide), the patient developed severe hypocalcaemia with tetany, which was treated 
successfully with intravenous calcium gluconate, oral calcitriol, and switching to hydrochlorothiazide. 
The patient was discharged on the following therapy, which she followed very carefully for a month before presenting to us: calcium carbonate 
3,000 mg/day, calcitriol 1 µg/day for hypoparathyroidism, levothyroxine (125 µg/day) for hypothyroidism, Warfarin for anticoagulant 
prophylaxis, hydrochlorothiazide (50 mg/day) and potassium chloride (1,800 mg/day by mouth).
The patient also reported taking, on her own initiative and initially undeclared, two herbal supplements for constipation, namely anthranoid 
laxatives (total anthraquinones 105 mg/day). 
The patient reported that calcitriol 0.5 µg/day had been sufficient to control her serum calcium since the thyroidectomy.
On examination, the patient was alert, confused and unsteady, with slurred speech. Pulse was 52 beats/minute and blood pressure 120/70 
mmHg. Laboratory data on admission were as follows: serum calcium, 21.2 mg/dl (normal range: 8.4–10.2); ionized calcium, 9.52 mg/dl 
(4.61–5.17); serum phosphorus, 2.7 mg/dl (2.7–5.1); chloride, 88 mg/dl (98–110); potassium, 2.4 mmol/l (3.5–5.5); blood urea nitrogen, 
56 mg/dl (5–25); creatinine, 4.36 mg/dl (0.5–1.4); serum bicarbonate, 38 mmol/l (24–31); arterial blood pH, 7.69; thyrotropin, 1.60 pU/ml 
(0.35–4.50); PTH, 4.8 pg/ml (6.0– 40.0); and 25(OH)D, 9.9 ng/ml (30–80). Chest x-ray was normal with no abnormalities. Ultrasound of the 
abdomen and head CT showed no relevant signs.
Initial treatment consisted of suspension of the patient’s home therapy and urgent dialysis, followed by intravenous NaCl 0.9%, loop 
diuretics and calcitonin. The treatment resulted in serum calcium reduction to 13.3 mg/dl and renal function improvement, although serum 
phosphorus dropped to 1.5 mg/dl. Potassium levels were normalized with intravenous and oral potassium chloride. Over the following 
3 days, the patient fully recovered her mental status, sensorium and speech. Serum calcium progressively dropped to 7.7 mg/dl, serum 
phosphorus rose to 3.8 mg/dl, serum potassium rose to 3.6 mmol/l, and PTH levels increased to 16.6 pg/ml. Consequently, the patient was 
restarted on intravenous calcium gluconate and calcitriol 0.25 µg/day, while intravenous potassium chloride was suspended. 
On the day of discharge, serum calcium was 7.5 mg/dl, creatinine was 1.54 mg/dl and blood urea nitrogen was 22.1 mg/dl. Since calcium 
supplementation was still required for treatment of the chronic hypoparathyroidism, the patient was discharged on a regimen of a non-
alkali calcium supplement (oral calcium citrate 1,200 mg/day) and calcitriol at her usual dose (0.50 µg/day), with recommendations to avoid 
any further alkaline calcium supplements and anthranoid laxative consumption. Other medicines for her comorbidities were prescribed. A 
6-month follow-up was scheduled to monitor calcium levels and adjust therapy dosages. 
DISCUSSION
This patient presented with the typical triad of milk-alkali syndrome, which consists of hypercalcaemia, metabolic alkalosis and renal failure. 
A 30-day history of high-dose calcium and absorbable alkali consumption was reported. 
Low-normal phosphate levels fell further,  which is common in the modern form of milk-alkali syndrome because of the chelating action of 
calcium carbonate, and low phosphorus intake. Potassium levels were low, which is consistent with diuretic use, metabolic alkalosis and 
chronic use of anthranoid laxatives.
The low PTH level, in line with her precedent residual baseline levels, was due to her post-surgical hypoparathyroidism. The increase in PTH 
levels concomitant with rebound hypocalcaemia after treatment with loop diuretics might also be suggestive of milk-alkali syndrome[2]. In 
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this case, PTH levels during rebound hypocalcaemia were significantly higher than the patient’s normal laboratory values.
Malignancy as a cause of the metabolic abnormality was excluded for the following reasons. The patient was 8 years free of cancer following 
surgery for papillary thyroid cancer, and biochemical parameters had been stable from thyroidectomy to her precedent hospitalization. 
Moreover, the metabolic abnormality had a relatively fast onset, and rapid normalization of the electrolyte values after suspension of 
calcium and alkali intake was observed.
Finally, tests for neoplastic markers were negative, and chest x-ray and abdomen ultrasound were negative for malignancy.
Low levels of 25(OH)D were present, excluding 25(OH)D intoxication; levels of 1,25(OH)
2
D were not measured. Since the patient had 
hypoparathyroidism, renal 1-hydroxylation of 25(OH)D into 1,25(OH)
2
D was reduced by low PTH levels, and also by chronic renal 
insufficiency. Therefore, the high-dose oral intake of calcitriol (1 µg/day) for hypoparathyroidism and the recent episode of hypocalcaemia, 




D levels could have caused 
an increase in the gastrointestinal fractional absorption of calcium carbonate, leading to milk-alkali syndrome. Moreover, the underlying 
chronic renal insufficiency might have inhibited calcium excretion by the kidney, thus contributing to the elevation of serum calcium levels. 
The onset of the acute renal insufficiency was due to the hypercalcaemia causing vasoconstriction of afferent arterioles and volume 
depletion. Alkalosis itself could have raised calcium levels by inhibition of calcium excretion (alkalosis stimulates TRPV5 Ca2+ channels on 
the apical membrane), initiating a spiral of increasing calcium levels. 
Furthermore, the patient was under treatment with hydrochlorothiazide[4], which has a specific action on the distal tubule, namely inhibition 
of sodium reabsorption and enhancement of calcium reabsorption, thus contributing to the elevation of serum calcium levels and fostering 
the increasing spiral. 
In this case, a final precipitating factor leading to the onset of milk-alkali syndrome might have been the anthranoid laxatives. Chronic use of 
anthranoid laxatives can cause electrolyte imbalance and enhance the potassium depletion effect of diuretics[5, 6]. Furthermore, some studies 
suggest that anthranoid laxatives can have nephrotoxic effects[7–11], namely alteration of the calcium excretion mechanism. We hypothesize 
a possible role for these anthranoid derivatives through diminishing calcium excretion.
CONCLUSIONS
Our experience underlines the need for caution when treating patients with impaired calcium metabolism regulation, as well as the 
importance of a thorough investigation of pharmacological history to identify undeclared drug self-administration. This is important for the 
assessment of calcium and alkali intake and for recognition of the effect on calcium metabolism of prescribed and over-the-counter drugs, 
which might be trigger factors for milk-alkali syndrome. Further studies on the interaction of anthranoid laxatives with calcium metabolism 
are needed since these herbal products are widely used and often unreported, and their pharmacological activity is frequently not known 
to either patients or physicians.
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